L2Mtech GmbH Receives CE Mark Approval on
6 (SIX) products for Cardiovascular and
CE Mark Approval for LimusTrackTM; LomiFlowTM; PearlFlowTM; PearlFlow NSTM; FlexiTrack 018TM and
FlexiTrack 035TM for Cardiovascular and Endovascular Applications
BONN, NRW, GERMANY, February 11, 2021 /EINPresswire.com/ — L2Mtech GmbH Founder and
CEO Lalit Mamtani said ‘‘We are very excited to have been awarded our first CE Mark on six
products, CE Mark approval represents a key milestone for L2Mtech GmbH and is a testament to
the efficacy and safety of our innovative technology products for Cardiovascular and
We now prepare to commercially launch the products in all markets where the CE Mark is
recognized. With introduction of our innovative technology products in markets, we will be able
to expand treatment options for the benefit of many millions of patients with coronary and
peripheral artery disease around the world.
L2Mtech GmbH has announced the award of its first CE Mark approval on Six (6) products:
LimusTrackTM : Sirolimus Coated Cobalt Chromium Stent with biodegradable polymer for the
treatment of coronary artery disease, de novo lesions, restenosis lesions.
LomiFlowTM : Paclitaxel Coated balloon catheter for the treatment of coronary artery disease,
small vessels, dilatation of de novo lesions, in-stent restenosis (ISR) cases .
PearlFlowTM : Paclitaxel Coated balloon catheter for the treatment of peripheral arterial disease,
PTA, dilatation of stenotic segments or lesions in peripheral arteries.
PearlFlow NSTM : Self-Expanding Nitinol Stent System for the treatment of peripheral arterial
disease, de novo lesions, lesions in femoropopliteal arteries.
FlexiTrack 018TM : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterial
disease, dilatation of lesions in femoral, popliteal, tibial arteries.
FlexiTrack 035TM : Peripheral Balloon Dilatation catheter for the treatment of peripheral arterialdisease, dilatation of lesions in the SFA, femoral arteries.
Founded in 2017, L2Mtech GmbH is a privately-owned multinational medical device company
headquartered at Bonn, Germany. L2Mtech specializes in design, development, manufacture
and commercialization of medical devices that are used by healthcare establishments globally.
L2MTech will provide interventional physicians with innovative vascular devices including Drug
Eluting Balloon manufactured in Europe. Our Core mission is to build a product portfolio focused
on minimally invasive treatment for patients with cardiovascular, endovascular and vascular
artery disease. For further information, please visit : www (dot) L2MTech (dot) de
+49 228 94730761
This press release can be viewed online at: https://www.einpresswire.com/article/535441720
EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors
try to be careful about weeding out false and misleading content. As a user, if you see something
we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,
Everyone’s Internet News PresswireTM, tries to define some of the boundaries that are reasonable
in today’s world. Please see our Editorial Guidelines for more information.
© 1995-2021 IPD Group, Inc. All Right Reserved.